Evidence map›Paper›PMID 41312016›Full record

ArticleMolecular therapy. Nucleic acids2025

Multivalent aptamer engineered and functionalized NK cells for enhanced adoptive immunotherapy in CD30-positive malignant lymphoma.

Fang Tan, Rui Wei, Jiqing Su, Cai Sheng, Qian Li, Yang Long, Xuyang Zhao, Liang Zhao, Shengpeng Huang, Lei Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Fang TanDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Rui WeiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Jiqing SuDepartment of Oncology, Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan 410004, China.
Cai ShengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Qian LiDepartment of Infection Diseases, Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan 410004, China.
Yang LongDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Xuyang ZhaoDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Liang ZhaoDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Shengpeng HuangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Lei ZhangDepartment of Neurology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Lu YangDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Hedong ZhangDepartment of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China.
Shuanghui YangDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Huan LiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adoptive cell therapy is a notable achievement in the treatment of various hematological malignancies. Among these cell-based therapies, chimeric antigen receptor natural killer (CAR-NK) cells have received increasing attention because, unlike CAR-T cells, they are not associated with the risk of cytokine release syndrome, immune-effector-cell-associated neurotoxicity syndrome, or graft-versus-host disease. CAR-NK cells have enhanced targeting properties and demonstrated therapeutic efficacy against various types of cancer. However, they face substantial challenges, including complex operational procedures, high cost associated with long-term use, and safety concerns. Aptamers are single-stranded oligonucleotides and known as "chemical antibodies" because of their highly specific binding ability to targets. In this study, we designed a multivalent aptamer oligonucleotide complex containing four strands of CD30 aptamers to engineer and functionalize NK cells using click chemistry. Under aptamer guidance, multivalent aptamer oligonucleotide complex NK cells specifically bind to CD30-positive lymphoma cells and trigger more effective antitumor effects than that of parental NK cells, both

Indexed as

adoptive cell therapyaptamersCD30-positive lymphomaDNA structuresMT: Oligonucleotides: Therapies and ApplicationsNK cells

Identifiers

PMID41312016
PMCPMC12650790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.